Intratumoral low oxygen tension promotes cancer cell invasion and metastasis. Hypoxia-Inducible Factor 1-alpha (HIF1α) is the principal transcription factor orchestrating cellular responses to hypoxic stress, mediating the regulation of genes implicated in adapting to perturbations in oxygen homeostasis. Here, we describe our findings that functionally demonstrate a nucleolar localization domain in HIF1ɑ that enables HIF1ɑ to translocate to the nucleolus. Nucleolar HIF1ɑ binds the ribosomal DNA promoter and upregulates RNA Polymerase I activity leading to dysregulated ribosomal RNA transcription and consequently enhanced ribosome biogenesis. Ribosome biogenesis is important in supporting cellular metabolic processes and invasion and metastasis. Our findings are recapitulated in breast tumors wherein upregulated HIF1ɑ and rRNA biogenesis are associated with poor prognosis. Finally, our studies demonstrate that inhibition of RNA Polymerase I impedes aggressive traits of hypoxia-driven cancer progression, highlighting the potential of this approach as a therapeutic strategy in breast cancer. Cumulatively our work unravels an unprecedented role of HIF1ɑ in regulating rRNA biogenesis in breast cancer.
Ovarian cancer incidence and mortality increase with age, yet how aging shapes tumor progression and the immune microenvironment remains poorly defined. Using orthotopic syngeneic models of distinct cellular origins (ovarian surface epithelial and fallopian tube-derived) in young versus aged mice, we show that aged hosts exhibit higher tumor burden, metastasis and ascites. Follicle depletion in young mice did not recapitulate these effects, indicating contributions beyond hormonal decline. Spatial transcriptomics revealed distinct age dependent intratumoral heterogeneity, with Hedgehog signaling enrichment in CD45 + cells from aged tumors, alongside elevated CD206 + tumor-associated macrophages and FoxP3 + regulatory T cells. Pharmacologic Hedgehog inhibition in aged mice suppressed tumor growth, reduced metastasis, and decreased CD206 + macrophages and FoxP3 + T cells while preserving CD8 + T cells. In human ovarian cancer, Hedgehog activation correlated with immunosuppressive and immune checkpoint resistance signatures. We propose Hedgehog inhibition as an immunomodulatory strategy for Hedgehog activated or post menopausal ovarian cancer.
Despite substantial advances in early detection and therapeutic strategies, breast cancer remains a major cause of cancer-related morbidity and mortality worldwide. Changes in cytoskeletal proteins that typically regulate cellular architecture underpin tumor progression. Merlin, encoded by the NF2 gene and a member of the ezrin–radixin–moesin protein family, functions as a critical cytoskeletal linker protein and a tumor suppressor that governs multiple oncogenic pathways and restricts epithelial–mesenchymal plasticity. While Merlin deficiency alters cellular architecture, the precise impact of a Merlin-deficient breast tumor on remodeling its immune microenvironment remains largely undefined. In this study, we demonstrate that in breast cancer, Merlin deficiency displays attributes consistent with enhanced epithelial–mesenchymal plasticity and enrichment of Hedgehog signaling. In vivo, Merlin-deficient tumors displayed accelerated growth and an immunosuppressive milieu characterized by increased abundance of regulatory T cells and M2-like macrophages. Treatment with Vismodegib, a pharmacological Hedgehog pathway inhibitor, reduced tumor growth of Merlin-deficient basal-like tumors, accompanied by a decrease in tumor-infiltrating regulatory T cells and immunosuppressive M2-like macrophages, and increased recruitment of pro-inflammatory M1-like macrophages. The data present Hedgehog inhibition as a targetable vulnerability of Merlin-deficient basal-like, triple-negative breast cancer.